Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.61 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.61 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.41 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6250294 | 0.80 | KDR (0.51) | BRAFKDRMAPK14TNNI3KTTBK1 | |
| SCHEMBL857777 | 0.79 | PTK6 (0.61) | BRAFKDRMAPK14TNNI3KTTBK1 | |
| SCHEMBL12518525 | 0.75 | MAP3K7 (0.70) | BRAFKDRMAPK14TNNI3KMET | |
| SCHEMBL30692257 | 0.75 | MAP3K7 (0.70) | BRAFKDRMAPK14TNNI3KMET | |
| SCHEMBL2283600 | 0.75 | KDR (0.68) | BRAFKDRMAPK14TNNI3KMET | |
| SCHEMBL12336390 | 0.73 | BRAF (0.62) | BRAFKDRMAPK14TNNI3KTTBK1 | |
| SCHEMBL857273 | 0.73 | NUDT1 (0.64) | BRAFKDRMAPK14TNNI3KAURKA | |
| SCHEMBL12336529 | 0.72 | BRAF (0.56) | BRAFKDRMAPK14TNNI3KTTBK1 | |
| SCHEMBL3247348 | 0.72 | AURKA (0.58) | BRAFKDRMAPK14TNNI3KAURKA | |
| SCHEMBL4548668 | 0.72 | KDR (0.71) | BRAFKDRMAPK14TNNI3KMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | BRAF 1615/4885KDR 4751/4885MAPK14 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.